CD28 and non-small cell lung carcinoma: Our study further confirmed these soluble molecules (CD28, CXCL10, TNFRSF9, TNFSF14, CD83, and HVEM) as predictive biomarkers in NSCLC, and might be potential targets to boost immunotherapy in patients.